Download Brochure

Track 25: Biopharmaceuticals

Introduction

Research in the area of bio pharmacology, often known as bio pharmacy, is closely related to pharmacokinetics.

Pharmaceuticals made with biotechnology are known as biopharmaceuticals. They are created using processes other than direct extraction from a native (non-engineered) biological source, and they include proteins (including antibodies) and nucleic acids (DNA, RNA, or antisense oligonucleotides) employed for therapeutic or in vivo diagnostic purposes.

Recombinant human insulin (rHI, brand name Hamelin), which was created by Genentech and commercialised by Eli Lily in 1982, was the first such drug to be licenced for therapeutic use.

Pharmaceuticals made from living things make up the vast majority of biopharmaceutical goods. The industry generally does not consider small molecule medications to be biopharmaceutical in nature. However, the concept is frequently expanded by members of the press, business community, and financial community to cover non-biotech medications. In other words, the phrase has evolved into a catchphrase frequently employed by a wide range of organisations developing novel, ostensibly high-tech medicinal goods.

SUBMIT YOUR ABSTRACTS

Download Abstract Sample

Our Speakers For 11th Global
Pharma Conference and Expo

The corporation will normally submit an application for a patent, which is a grant of exclusive manufacturing rights, when a biopharmaceutical is created. This is the main method by which the drug's creator can recoup the money spent on the biopharmaceutical's development. The conditions for a patent varies slightly between the patent laws of the United States and Europe, with the European requirements being thought to be more challenging to meet. Since the 1970s, a significant increase in the overall number of biopharmaceutical patents has been awarded. There were 30 total patents granted in 1978. As of 2001, there were 34,527 patent applications, up from 15,600 in 1995.

The Food and Drug Administration (FDA) in the United States has tight regulations governing the commercial distribution of pharmaceutical products, including biopharmaceuticals. Many years of clinical testing, including testing on human volunteers, may be necessary for approval. The medicine will continue to be examined for performance and safety hazards even after it is made available.

The FDA's "current Good Manufacturing Practices" rules must be followed during the drug's production. They are normally produced in a clean room setting with predetermined limits on airborne particle levels.